Researchers have found that renal denervation in patients with hypertension is associated in significant improvements in systolic blood pressure.

The proposed NCD, released on July 10, 2025, recommends coverage for ultrasound renal denervation (uRDN) and radiofrequency renal denervation (rfRDN) for uncontrolled hypertension. A 30-day public ...

Palo Alto, CA, July 10, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced their ...

Investing.com - Medtronic , Inc. (NYSE:MDT) is expected to trade higher following the Centers for Medicare & Medicaid Services’ (CMS) proposed decision memo for renal denervation (RDN) treatment for ...

In other recent news, Medtronic, Inc. has received a proposed National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS) for its Renal Denervation (RDN) therapy.

See what all the critics had to say about Moulin Rouge! with Broadway World! Read the most influential Moulin Rouge! Broadway and Off-Broadway reviews here!

The proposed determination recommends Medicare coverage for both radiofrequency- and ultrasound-based renal denervation.

Deepqure Inc. gained clinical trial clearance from South Korea’s Ministry of Food and Drug Safety to test its Hyperqure renal denervation system for the treatment of atrial fibrillation.

Investing.com - Medtronic (NYSE: MDT) received positive news as the Centers for Medicare & Medicaid Services (CMS) published a proposed National Coverage Determination (NCD) for renal denervation (RDN ...

Investing.com - The Centers for Medicare & Medicaid Services (CMS) released its proposed National Coverage Decision for Renal Denervation therapy on Wednesday, potentially benefiting Medtronic , Inc. ...